Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
nL-SAA1-01 in AA Amyloidosis
NCT06397001Phase 1Completed
- Start
- Nov 2023
- Primary completion
- Dec 2024
- Modality
- Modified DNA Oligonucleotides, Single-strand DNA, Antisense Oligonucleotides (ASOs)
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of nL-SAA1-01 in AA amyloidosis. Primary endpoint: Adverse Events and/or serious adverse events at 1 year. Started Nov 2023; status: completed.
02
Drugs
nL-SAA1-01
03
Conditions
AA amyloidosis
Beyond the preview
Go deeper on NCT06397001.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06397001.